Skip to main content

Clinical Management of Hereditary Colorectal Cancer

  • Chapter
  • First Online:
Recent Advances in the Treatment of Colorectal Cancer

Abstract

Lynch syndrome (LS) is an autosomal dominant inherited syndrome characterized by the development of early-onset colorectal cancer (CRC), endometrial cancer, and other cancers. Universal tumor screening for detection of LS in all CRC and endometrial cancer patients tends to be popular instead of use of conventional clinical guidelines. Immunohistochemistry of mismatch repair proteins appears to be favorable compared to microsatellite instability (MSI) testing in terms of identification of the causative gene. The surveillance for individuals with LS is established in CRC and gynecological cancer depending on the causative genes, while there are still no evidences in other LS-associated cancers. Among adenomatous polyposis syndrome, more than 100 polyps clinically come up with the diagnosis of familial adenomatous polyposis (FAP). If the number of polyps is less than 100, germline genetic testing of the APC, MUTYH, POLE, and POLD1 genes should be needed to make an accurate diagnosis. Early diagnosis and management is required due to complete penetrance and an almost 100% lifetime risk of CRC without intervention in FAP patients. In addition to CRC, the screening of duodenal cancer and desmoid tumors should be routinely performed to prevent the mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.

    Article  CAS  Google Scholar 

  2. Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308:485–92.

    Article  CAS  Google Scholar 

  3. Vasen HF. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol. 2000;18:81S–92S.

    CAS  PubMed  Google Scholar 

  4. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.

    Article  CAS  Google Scholar 

  5. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med. 1966;117:206–12.

    Article  CAS  Google Scholar 

  6. Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555–65.

    Article  CAS  Google Scholar 

  7. Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut. 2012;61:865–72.

    Article  Google Scholar 

  8. Katz LH, Burton-Chase AM, Advani S, et al. Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome. Clin Genet. 2016;89:392–8.

    Article  CAS  Google Scholar 

  9. Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol. 2015;21:9253–61.

    Article  CAS  Google Scholar 

  10. Geurts-Giele WR, Leenen CH, Dubbink HJ, et al. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers. J Pathol. 2014;234:548–59.

    Article  CAS  Google Scholar 

  11. Haraldsdottir S, Hampel H, Tomsic J, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014;147:1308–16.

    Article  Google Scholar 

  12. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014;146:643–6.

    Article  CAS  Google Scholar 

  13. Rodríguez-Soler M, Pérez-Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013;144:926–32.

    Article  Google Scholar 

  14. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293:1979–85.

    Article  CAS  Google Scholar 

  15. Abdel-Rahman WM, Ollikainen M, Kariola R, et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene. 2005;24:1542–51.

    Article  CAS  Google Scholar 

  16. Kohda M, Kumamoto K, Eguchi H, et al. Rapid detection of germline mutations for hereditary gastrointestinal polyposis/cancers using HaloPlex target enrichment and high-throughput sequencing technologies. Familial Cancer. 2016;15:553–62.

    Article  CAS  Google Scholar 

  17. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.

    Article  CAS  Google Scholar 

  18. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999;36:801–18.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Lynch HT, Lynch JF, Attard TA. Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model. CMAJ. 2009;181:273–80.

    Article  Google Scholar 

  20. Sehgal R, Sheahan K, O'Connell PR, Hanly AM, Martin ST, Winter DC. Lynch syndrome: an updated review. Genes (Basel). 2014;5:497–507.

    Article  Google Scholar 

  21. Ishida H, Yamaguchi T, Tanakaya K, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the clinical practice of hereditary colorectal cancer (translated version). J Anus Rectum Colon. 2018;2:S1–S51.

    Article  Google Scholar 

  22. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010;102:193–201.

    Article  CAS  Google Scholar 

  23. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135:419–28.

    Article  CAS  Google Scholar 

  24. Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J Cutan Pathol. 2009;36:613–9.

    Article  Google Scholar 

  25. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60:950–7.

    Article  Google Scholar 

  26. Kim TJ, Kim ER, Hong SN, et al. Survival outcome and risk of metachronous colorectal cancer after surgery in Lynch Syndrome. Ann Surg Oncol. 2017;24:1085–92.

    Article  Google Scholar 

  27. Adachi M, Banno K, Yanokura M, et al. Risk-reducing surgery in hereditary gynecological cancer: clinical applications in Lynch syndrome and hereditary breast and ovarian cancer. Mol Clin Oncol. 2015;3:267–73.

    Article  Google Scholar 

  28. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–27.

    Article  CAS  Google Scholar 

  29. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.

    Article  CAS  Google Scholar 

  30. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103:863–75.

    Article  CAS  Google Scholar 

  31. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

    Article  CAS  Google Scholar 

  32. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717–26.

    Article  CAS  Google Scholar 

  33. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;34:2460–7.

    Article  CAS  Google Scholar 

  34. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623–30.

    Article  CAS  Google Scholar 

  35. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.

    Article  CAS  Google Scholar 

  36. Balmaña J, Balaguer F, Cervantes A, Arnold D, ESMO Guidelines Working Group. Familial risk-colorectal cancer: ESMO clinical practice guidelines. Ann Oncol. 2013;24:vi73–80.

    Article  Google Scholar 

  37. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–7.

    Article  Google Scholar 

  38. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.

    Article  Google Scholar 

  39. Vasen HF, Taal BG, Nagengast FM, et al. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur J Cancer. 1995;31A:1145–8.

    Article  CAS  Google Scholar 

  40. Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 2005;331:1047.

    Article  Google Scholar 

  41. Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010;138:2300–6.

    Article  Google Scholar 

  42. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812–23.

    Article  CAS  Google Scholar 

  43. National Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: colorectal version 3. 2017. https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Accessed 10 Oct 2017.

  44. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62.

    Article  Google Scholar 

  45. Aretz S, Uhlhaas S, Caspari R, et al. Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet. 2004;12:52–8.

    Article  CAS  Google Scholar 

  46. Nielsen M, Franken PF, Reinards TH, et al. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet. 2005;42:e54.

    Article  CAS  Google Scholar 

  47. Nieuwenhuis MH, Bülow S, Björk J, et al. Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery. Dis Colon Rectum. 2009;52:1259–63.

    Article  Google Scholar 

  48. Petersen GM, Slack J, Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology. 1991;100:1658–64.

    Article  CAS  Google Scholar 

  49. Byrne RM, Tsikitis VL. Colorectal polyposis and inherited colorectal cancer syndromes. Ann Gastroenterol. 2018;31:24–34.

    PubMed  Google Scholar 

  50. Vasen HF, Tomlinson I, Castells A. Clinical management of hereditary colorectal cancer syndromes. Nat Rev Gastroenterol Hepatol. 2015;12:88–97.

    Article  Google Scholar 

  51. Fallen T, Wilson M, Morlan B, Lindor NM. Desmoid tumors—a characterization of patients seen at Mayo Clinic 1976-1999. Familial Cancer. 2006;5:191–4.

    Article  Google Scholar 

  52. Belchetz LA, Berk T, Bapat BV, Cohen Z, Gallinger S. Changing causes of mortality in patients with familial adenomatous polyposis. Dis Colon Rectum. 1996;39:384–7.

    Article  CAS  Google Scholar 

  53. Burt RW, Leppert MF, Slattery ML, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology. 2004;127:444–51.

    Article  Google Scholar 

  54. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57:704–13.

    Article  CAS  Google Scholar 

  55. Kartheuser A, Stangherlin P, Brandt D, Remue C, Sempoux C. Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited. Familial Cancer. 2006;5:241–60.

    Article  Google Scholar 

  56. Church J. In which patients do I perform IRA, and why? Familial Cancer. 2006;5:237–40.

    Article  Google Scholar 

  57. Koskenvuo L, Mustonen H, Renkonen-Sinisalo L, Järvinen HJ, Lepistö A. Comparison of proctocolectomy and ileal pouch-anal anastomosis to colectomy and ileorectal anastomosis in familial adenomatous polyposis. Familial Cancer. 2015;14:221–7.

    Article  CAS  Google Scholar 

  58. Ueno H, Kobayashi H, Konishi T, et al. Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan. Int J Clin Oncol. 2016;21:713–22.

    Article  CAS  Google Scholar 

  59. Konishi T, Ishida H, Ueno H, et al. Feasibility of laparoscopic total proctocolectomy with ileal pouch-anal anastomosis and total colectomy with ileorectal anastomosis for familial adenomatous polyposis: results of a nationwide multicenter study. Int J Clin Oncol. 2016;21:953–61.

    Article  Google Scholar 

  60. Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet. 1989;2:783–5.

    Article  CAS  Google Scholar 

  61. Alexander JR, Andrews JM, Buchi KN, Lee RG, Becker JM, Burt RW. High prevalence of adenomatous polyps of the duodenal papilla in familial adenomatous polyposis. Dig Dis Sci. 1989;34:167–70.

    Article  CAS  Google Scholar 

  62. Yao T, Ida M, Ohsato K, Watanabe H, Omae T. Duodenal lesions in familial polyposis of the colon. Gastroenterology. 1977;73:1086–92.

    CAS  PubMed  Google Scholar 

  63. Chung RS, Church JM, vanStolk R. Pancreas-sparing duodenectomy: indications, surgical technique, and results. Surgery. 1995;117:254–9.

    Article  CAS  Google Scholar 

  64. Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG, et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer. 2011;104:37–42.

    Article  CAS  Google Scholar 

  65. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100:612–20.

    Article  CAS  Google Scholar 

  66. Church J, Lynch C, Neary P, LaGuardia L, Elayi E. A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis. Dis Colon Rectum. 2008;51:897–901.

    Article  Google Scholar 

  67. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101:385–98.

    Article  Google Scholar 

  68. Koskenvuo L, Renkonen-Sinisalo L, Järvinen HJ, Lepistö A. Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis. Int J Color Dis. 2014;29:225–30.

    Article  CAS  Google Scholar 

  69. Campos FG, Perez RO, Imperiale AR, Seid VE, Nahas SC, Cecconello I. Surgical treatment of familial adenomatous polyposis: ileorectal anastomosis or restorative proctolectomy? Arq Gastroenterol. 2009;46:294–9.

    Article  Google Scholar 

  70. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6:105–10.

    Article  CAS  Google Scholar 

  71. Phillips M, Dicks-Mireaux C, Kingston J, et al. Hepatoblastoma and polyposis coli (familial adenomatous polyposis). Med Pediatr Oncol. 1989;17:441–7.

    Article  CAS  Google Scholar 

  72. Iwama T, Mishima Y. Mortality in young first-degree relatives of patients with familial adenomatous polyposis. Cancer. 1994;73:2065–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kensuke Kumamoto .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kumamoto, K., Ishida, H. (2019). Clinical Management of Hereditary Colorectal Cancer. In: Ishida, H., Koda, K. (eds) Recent Advances in the Treatment of Colorectal Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-13-3050-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-3050-6_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-3049-0

  • Online ISBN: 978-981-13-3050-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics